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Abstract 
The first project discussed was aimed at further expanding on coculture and 
culture induction techniques in extremophilic fungi under the supervision of Dr. Andrea 
Stierle and Dr. Donald Stierle. Quantitative testing of crude and purified compounds was 
accomplished using Alamar Blue Assays through our collaboration with the Priestley Lab 
at the University of Montana. Qualitative changes were tracked with reverse-phase liquid 
chromatography-quantitative time of flight (RPLC-QTOF) and proton NMR 
spectroscopy (1H-NMR) through the Mass Spectroscopy and NMR cores at the 
University of Montana. The second portion of this thesis deals with the expression, 
purification, and crystallization of human caspase-1 and human caspase-3 with natural 
product inhibitors under the supervision of Dr. T.C. Mou with help from the University 
of Montana crystallography core facility and the Sprang Lab.  
These projects aimed to further expand on natural product techniques as they 
pertain to the discovery of chemical scaffolds with useful antimicrobial and anti-
inflammatory activity. This was done through the application of cultutre induction using 
methanol and protein crystallography.  
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Chapter 1. Introduction to Drug Discovery 
 
Section 1. Introduction to Natural Products 
Introduction to Natural Products 
 “Natural products are small molecules produced naturally by any organism 
including primary and secondary metabolites” (https://www.nature.com/subjects/natural-
products). Natural products were the first antibiotics, the first anti-inflammatories, and 
some of the first psychoactive compounds to be used clinically (Dias et al. 2012). While 
recorded history from these times can be difficult to track, and often delves into the realm 
of mythology, it is thought that traditional Chinese medicine (TCM) was developed by 
Shennong around 4,500 years ago, when he compiled the original text “Ben Cao Jing” or 
“Shen Nong Ben Cao Jing” (translates to “Divine Farmer’s Classic of Materia Medica” 
among numerous other translations). In this text, 365 traditional Chinese medicines are 
described by their physical appearance, taste, and their effect on the human body. 
(Foreword to “The Divine Farmer’s Materia Medica: A Translation of the Shen Nong Ben 
Cao” by Shou-Zhong Yang (Editor)). As the process has become more refined, so too has 
the application of natural products from a more primitive manner (chewing on bark or other 
useful plants) to the quantitative realm of modern pharmacy (Moloney MF. 1919. Irish 
ethno-botany and the evolution of medicine in Ireland. Dublin: MH Gill and Son; 
Bernardini et al. 2017, Stierle et al. 2017, Khalil  et al. 2018).  
As pharmaceutical science moved into the 19th and 20th century, greater focus was 
put on the effects of a single compounds isolated from natural sources (Dias et al. 2012; 
Bernardini et al. 2017; Chen et al. 2018). This would consist of harvesting natural sources 
of a compound or by fermentation techniques, which are then processed and purified to 
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yield the active components. This has been exemplified via the discovery of a number of 
clinically relevant antibiotics including penicillin, erythromycin, and vancomycin 
(Newman and Cragg 2016; Jakubiec-Krzesniak et al. 2018) and anticancer agents including 
epothilone and taxol (B da Rocha et al. 2001; Kinghorn et al. 2009; Newman, Grothaus, 
Cragg 2009).  
As the science of natural products chemistry emerged into the modern age, the 
processes used to culture the organisms with desired chemistry has left much to be desired, 
resulting in recurring isolation of known compounds along with those deemed pan-assay 
interfering compounds [pan-assay interference compounds (PAINS) cause false-positive 
assay signals due to reactivity under assay conditions, including covalent modifications or 
redox effects, chelation, autofluorescence, or degradation. Invalid metabolic panaceas 
(IMPS) are compounds that are active against numerous biological/pharmacological 
endpoints] (Vederac et al. 2009; Whitty 2011).  
Given the challenge of identifying new compounds from natural sources, more 
creative and modern molecular and computational approaches have become popular in the 
effort to produce novel, bioactive natural products. These include mining for the gene 
clusters associated with new compounds combined with synthetic biology (Bradley et al. 
2016, Biggs et al. 2014, 2016), growing previously cultured organisms together (Stierle et 
al 2017; Onaka 2017; Khalil et al. 2018), through induction of previously cultured 
organisms with small molecules (Martin et al. 2011) and biomolecules (Schmidt et al. 
2014) or using new culturing techniques (Nichols et al. 2011, Ling et al. 2015). While these 
techniques vary in technical approach, the end goal is very much the same: producing new 
compounds or increasing the production of previously low yield compounds. Varied 
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growth conditions and techniques involving coculture and induction can result in the 
activation of defense mechanisms without resorting to direct genetic manipulation. These 
techniques can help impart improved survival by sequestering toxic metabolites or by 
fighting off competitors and attackers via the production of repressed or under-represented 
secondary metabolites (Mazid et al. 2011; Roze et al. 2011). 
 
Drug Discovery and Infectious Disease 
In recent years, with the rise of multidrug-resistant bacteria and the prevalence of 
resistance in infectious diseases, there has been a call for novel structures with useful 
antimicrobial activity, a trend that is even more evident once the ESKAPE pathogens 
(Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter 
baumannii, Pseudomonas aeruginosa, and Enterobacter species) are considered. These 
are strains of clinically relevant pathogens that have shown antibiotic resistance in 
nosocomial infections (Santajit and Endrawattana, 2016). With the danger of antibiotic 
resistance on the rise, the need for newer antibiotics is becoming more and more 
imperative. The World Health Organization (WHO) proposes that drug resistance 
“threatens the effective prevention and treatment of an ever-increasing range of infections 
caused by bacteria, parasites, viruses, and fungi”. (http://www.who.int/news-room/fact-
sheets/detail/antimicrobial-resistance; Prestinaci et al, 2015) For therapies to have the 
utmost longevity of use, novel structures with antibiotic activity are needed to avoid pre-
existing resistance mechanisms.  
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Brief History of Naturally Derived Antibiotics 
Natural products chemistry remains a promising pathway to the discovery of novel 
structures with beneficial antibiotic activity.  In reviews published by Newman and Cragg 
in 2016, it is reported that 60% of drug approvals are based on natural product scaffolds 
(Newman and Cragg 2008, 2016). This suggests the method of drug discovery from natural 
products has had a long history of producing new pharmaceuticals. One of the most notable 
natural products is penicillin produced by the fungus Penicillium notatum (now P. 
chrysogenum) and isolated by Alexander Fleming in 1928. This discovery would ignite 
what we now refer to as the golden age of antibiotics, during which time many other 
valuable compounds were discovered including streptomycin, the cephalosporins, 
aminoglycosides, and vancomycin (Davies 2006) This antibiotic boom also produced 
several Nobel laureates, including Fleming in 1945 (honoring his discovery of penicillin in 
1928), Selman Waksman in 1952 for the discovery of streptomycin from Actinomyces 
griseus, a soil bacterium (Schatz et al. 1944; Woodruff 2014), and Robert Woodward in 
1965 for his synthesis of a number of natural products, including the clinically relevant 
macrolide antibiotic erythromycin (Woodward et al. 1981). More recently, Youyou Tu, 
Satoshi Omura, and William Campbell were awarded a Nobel prize in 2015 for their work 
in the discovery of artemisinin (a widely used antimalarial), avermectin, and the 
semisynthesis of ivermectin from avermectin (the cure for river blindness), respectively. 
Qinghaosu (modern day Artemisinin) is a natural product isolated from Qinghao (sweet 
wormwood, Artemisia annua), which was first described in traditional Chinese medicine 
as a treatment for malaria. In the early 1970s, Youyou Tu discovered the need for a cold 
extraction of Qinghao to preserve the peroxide bridge moiety of artemisinin which is 
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responsible for its activity. She also determined the structure of artemisinin and was 
involved in conducting the first human clinical trials for artemisinin (Antimalarial Studies 
on Qinghaosu, 1979; Faurant 2011; Su and Miller, 2015). The case of avermectin and 
Ivermectin will be discussed in further detail in the next chapter. 
 
Bioassay-Guided Fractionation 
Bioassay-guided fractionation provides a rational approach to following activity 
from a crude extract to a bioactive, purified compound. This process involves extensive 
testing of crude extracts and the chromatographic fractions produced at each step of the 
purification process. This process has been employed by the Stierle Lab and several others 
to yield bioactive compounds in high purity and allows a researcher to effectively track 
activity from a crude extract down to a purified compound. Until 2016, the primary focus 
of the Stierle research laboratory has been the isolation of novel compounds that inhibit the 
enzymes caspase-1, caspase-3, or MMP-3. In the last two years they have also begun 
looking for compounds with antibiotic activity (Stierle et al 2017). 
Caspase-1 has been shown to be up-regulated in pathologies including cancer, 
autoimmune disease and inflammation (ref.) Caspase-3 is a key enzyme in apoptosis and 
has been implicated in penumbral damage following stroke, and in the onset of Alzheimer’s 
disease, MMP-3 has been implicated in epithelial mesenchymal transition, a key 
component of cancer metastasis. These pathologies all represent clinically relevant 
conditions, to which drug discovery could have a meaningful impact in reducing death and 
human suffering.  
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Examples of Biosynthetic Machinery 
The production of naturally occurring compounds from an organism can involve 
any of several quintessential enzyme systems, held under varying degrees of regulatory 
control. Induction of these pathways can yield higher amounts of previously identified 
secondary metabolites, as well as novel secondary metabolites not seen under standard 
growth conditions.  
The pathways for generating bioactive structures can often be very complicated in 
their cascade hierarchy, function, and expression patterns. Additionally, the proteins in 
these pathways usually originate from more universal biosynthetic pathways, such as 
steroid synthesis, to produce the corresponding small molecules. These similarities mean 
many of the precursors, the chemistry involved, and the resulting products share similarity 
between their native source. For the sake of brevity, two general classes of biosynthetic 
proteins will be superficially described. 
One of the most common classes of biosynthetic machinery is that of the polyketide 
synthases (PKSs). These enzymes are generally derived from proteins in the fatty acid and 
steroid synthesis pathways. This class consists of three individual archetypes (I-III), based 
on the overall assemblage of their active sites. These can be housed on one megasynthase 
protein (type I), on multiple, physically associated proteins (Type II), or via several 
individual proteins working in a given syntax (Type III) (Smith et al, 2007).  
The nonribosomal peptide synthases (NRPSs) represent a second class of 
biosynthetic machinery. NRPSs are involved in the synthesis of peptide-like natural 
products (Daptomycin, Bleomycin) along with cyclic dipeptides called 2,5-
diketopiperazines (Cialis/Tadalafil). 2,5-diketopiperazines are the synthetic result of 
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linking 2 amino acids N-terminus to C-terminus in a 6-member heterocycle containing 2 
amide bonds (a 2,5-diketopiperazines) with the sidechains of the associated amino acid 
precursors (Strieker et al. 2011; Vila-Farres et al. 2017).  
These examples are just a small subset of the various ways that cells have 
repurposed metabolic pathways for small molecule production. However, the field of 
biosynthetic machinery is immense and is not within the scope of this thesis. Often these 
sets of biosynthetic machinery are encoded within a cluster of genes which are under 
control of promoters. These gene clusters often involve regulatory and functional elements 
that might impart some form of resistance to the producer of said secondary metabolite via 
expression of catabolic enzymes or efflux proteins. These are referred to as biosynthetic 
gene clusters (BGCs), the activation of which results in the expression of all necessary 
elements for secondary metabolite production and regulation. While it is not uncommon 
for a singular organism’s genome to contain several of these BGCs, only a select number 
of them are expressed under normal laboratory conditions. (Rutledge and Challis, 2015). 
The classic bacterial operon is regulated by a single promoter for a set of genes. BGCs 
diverge from this definition in that BGCs are controlled modularly, by several different 
promoters (Osbourn et al. 2009). 
 
Section 2. Background for Growth and Induction 
Impacts of Simple Media and Singular Inoculum 
Historically, laboratory cultivation of microbes has focused on singular inoculum 
and monocultures, a trend dictated by the need for high reproducibility (Stierle et al. 2006, 
8 
 
2007, 2008, 2014). However, culture-induction and coculture techniques have recently 
been making headway as a means of producing novel secondary metabolites from 
previously explored microbes (Stierle et al. 2017, Onaka 2017; Khalil et al. 2018). These 
techniques utilize a phenomenon referred to as cryptic biosynthesis, where key producer-
inducer interactions induce the expression of BGCs that would lie dormant under normal 
laboratory conditions (Nickerson et al 2006; Semighini et al. 2006; Khalil et al. 2014; 
Wakefield et al. 2017). These gene clusters are generally geared toward the production of 
host-defense mechanisms, imparting a degree of evolutionary robustness when the target 
microbe is challenged with competition (Mazid et al. 2011; Roze et al. 2011). This 
activation can be due to either direct contact, communally shared metabolites, genetic 
modification, or, hypothetically, a mix of all three. In the case of the berkeleylactones, the 
Stierles used coculture to induce the production of a series of new small molecules not 
previously observed in either of the involved strains. Given the nature of Berkeleylactone 
A, it would seem coculture is inducing the expression of polyketide synthases.  
Specific BGCs may be activated through a symbiotic relationship, known as 
evolutionary pairing, or by exposure to a compound that had previously been a part of the 
organism’s native environment (Rutledge and Challis, 2015; Stierle et al. 2017; Khalil et 
al. 2018). Sarikaya-Bayram et al. described the role of VeA and other velvet-like proteins 
in the growth and maturation of fungi and secondary metabolite production. This is thought 
to be brought about by interactions with LaeA, a methyltransferase capable of regulating 
secondary metabolism in Aspergillus species through activation of metabolic gene clusters 
(Bok et al. 2004; Hong et al. 2015). This leads to the concept of cryptic biosynthesis, where 
BGCs can be activated through nontraditional means, such as induction with new culture 
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media, addition of a small molecule or peptide/biomolecule, or induction in a coculture 
environment. Additionally, organisms may use autoinduction pathways that rely on the 
production and accumulation of molecules that trigger changes in gene expression 
(positively or negatively), which is termed quorum sensing, or by blocking such pathways 
(quorum quenching) (Nickerson et al. 2006; Semighini et al.). The role of gene expression 
in secondary metabolite production opens up a number of avenues to access, predict, and 
stimulate these kinds of interactions, whether from an ecological, biochemical, epigenetic, 
or bioinformatic stand point.  
 
The Story of Berkeleylactone A 
Ecologically-derived induction can involve stimulation with molecules from the 
organism’s native environment (for example, using sulfuric acid to acidify broths) or by 
utilizing organisms that come from the native environment (coculture; Stierle et al 2017). 
This represents one of the most obvious approaches for stimulating the production of novel 
secondary metabolites. The approach of coculture involves taking organisms from the 
producer strain’s native environment (such as a symbiont or a competing organism) and 
adding it into the culture of the producer strain (Wakefield et al. 2017; Stierle et al 2017; 
Khalil et al 2018). The production of the novel scaffolds emericellamide A and B were 
induced in a marine fungus Emericella sp. by coculture with a marine actinomycetes, 
Salinispora arenicola.  
This methodology was the underlying principle behind the Stierle Lab’s discovery 
of the berkeleylactones. Both were extremophilic Penicillium sp. that had been isolated 
from the surface water of the Berkeley Pit, a mine waste site located in Butte, Montana. 
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The significance of finding life in the water at this location has been noteworthy (Bociaga 
and Mitman 2003) and has provided the Stierle Lab with a plethora of work over that last 
2 decades (Stierle 2008, 2017). In Stierle et al. 2017, the symbiotic relationship between 
two extremophilic fungi was utilized to produce a series of novel macrolide antibiotics 
through cryptic biosynthesis. The producer strain used was Penicillium 
clavigerum/camimbertii (designated PW2B) and the inducer strain was Penicillium fuscum 
(designated PW2A). The secondary metabolites produced via coculture included a known 
compound previously described by Eli-Lily in 1973 (A26771B; Michel et al. 1977), along 
with several new macrolides named the berkeleylactones (figure 1, Page 13). Michel had 
also identified a series of compounds labeled A26771A through E, which showed varying 
degrees of antibiotic activity. These compounds included Gliovictin and hyalodendrin, 
which had been identified and antiviral and antibiotic (Michel et al 1974). The lead 
compound, berkeleylactone A shows antibiotic activity against multiple strains of both 
hospital-acquired and community-acquired MRSAs, S. pyogenes, and B. anthracis. 
Conventional macrolide antibiotics are large cyclic structures such as erythromycin, 
clindamycin, and azithromycin usually assembled from propionate and a number of acetate 
units into a macrocyclic ester. This results in 14, 15, or 16 membered rings with several 
points of oxidation along their carbon backbone. Although the berkeleylactones are 
classified as macrolide antibiotics, they differ from the canonical macrolides 
(erythromycin, clindamycin, etc.) in two important structural features: 
• The berkeleylactones lack the sugar moieties associated with both the 
antibiotic activity and the induction of bacterial resistance associated with 
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canonical macrolides. This suggests that the macrolides ay have a lower risk 
of triggering resistance. 
 
• The biosynthesis of berkeleylactone is based on incorporation of 
polyacetate moieties while that of canonical macrolides is based on 
polyproprionate moieties,which is exemplified with DEBS synthase, the 
biosynthetic machinery used to produce a key erythromycin precursor,    6-
deoxyerythonolide B (Edwards et al 2014).    
The application of extremophilic coculture exemplifies rational methodologies for the 
activation of previously silent BGCs in the production of new, bioactive secondary 
metabolites.    
The usual mode of action for macrolide antibiotics involves the inhibition of protein 
synthesis via ribosomal binding, a process not observed with berkeleylactone A (Stierle et 
al. 2017). Alexander Mankin’s Lab at University of Illinois demonstrated that the antibiotic 
activity of berkeleylactone A is not associated with ribosomal interaction. This suggests 
that its mechanism of action is unlike that of conventional macrolides. This was done by 
examining the size protein fragments produced by a ribosome during exposure to a 
selection of known macrolide antibiotics and berkeleylactone A. This provides information 
on the target molecule’s ability to stall protein production at a given codon or residue 
number. Stalling of the ribosomal complex results in short peptide sequences that invoke 
the activity of erm, a RNA methyl transferase that modifies an adenine residue in the 23S 
ribosomal subunit, imparting macrolide resistance and subsequent cell viability (Maravic 
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2004, Arenz et al. 2014) In the case of berkeleylactone A, the full peptide chain was 
synthesized, suggesting its lack of activity towards the ribosome. 
 
Nutrient and Media-Based Induction 
Alternatives to coculture involve induction of an organism’s BGCs with small 
molecules. This involves two general methodologies: (1) providing a substantial amount 
of precursor for the generation of novel or under-represented secondary metabolites 
(Ajikumar et al. 2010; Biggs et al. 2014) or (2) induction of BGCs by addition of 
components to the media that induce the production of new compounds. An inducer could 
be considered distinct from a component of media in that you would not expect an inducer 
to be incorporated into the induced product. IPTG would be the classic example, in that it 
is often used in protein expression as a lac-operon inducer but is not incorporated into the 
produced protein product (Mittl et al 1997; Martin et al. 2011; Vander-Molen et al. 2013; 
Vogel et al 2018). Historically, the former has been assessed through direct addition of 
precursors (e.g. adding farnesol or acetate), or by simply changing the nutrient sources in 
the media (glucose in media switched to lactose) (Ghorbani-Nasrabadi et al. 2013). This 
can also be accomplished either by direct modification of the media composition as 
described previously, or by adding a solvent, such as DMSO, to facilitate uptake of 
precursors (Li et al. 2012).  
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Figure 1. Berkeleylactones and the A26771 series (Top) Stuctures of Berkeleylactone 
series and A26771B (Figure from Stierle et al 2017) (Bottom) A26771A (I, Gliotoxin) 
A26771C (II, S2-Hyalodenrin) A26771D (III, S4-Hyalodenrin) A26771E (IV, Gliovictin) 
(Figure from Michel et al 1973). 
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These tactics helped modulate the producing strain’s access to nutrients - or to 
specific precursors of desired secondary metabolites - boosting production of secondary 
metabolites (Biggs et al. 2014, 2016).  This may result in either increased production of a 
secondary metabolite via precursor access, or novel compounds by continued enzymatic 
action on said secondary metabolite, which might otherwise not be able to reach the cellular 
location for modification (Yang et al. 2014; Biggs et al. 2014, 2016)  
This can be exemplified by the work done by Biggs et al. in 2014 and 2016 where 
they describe a multivariate modular metabolic engineering (MMME) technique. This 
process approaches synthetic biology from a module-based paradigm and was applied to 
the production of taxol, a secondary metabolite of the Taxus brevifolia, the Northwest 
Pacific yew tree, as well as certain fungi, (Stierle et al. 1993) in an engineered E. coli strain. 
This process allowed for tight control of precursor generation, resulting in improved 
metabolite production over previously employed techniques. This was due to a rate limiting 
step partway through the synthesis, which resulted in the accumulation of metabolites that 
were then modified into aberrant compounds not conducive to taxene-5α-ol production. 
When gene inducers were applied with varying strength (increasing copy number, using 
different promoters) rate limiting steps could be accounted for, controlling and optimizing 
the production of the metabolite taxene-5α-ol. 
 
Effects of LPS on Secondary Metabolite Production in Filamentous Fungi 
In 2014, Capon et al. examined the effects of induction with LPS on several fungi 
and bacteria, including a variety of Penicillium strains. This research provided insight into 
a mechanism for inducing the production of secondary metabolites after exposure to cell-
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wall constituents associated with gram-negative bacteria. LPS was added to cultures of 
Penicillium sp. at 100 – 0.01 ng/mL and serendipitously resulted in the production of 
pseurotin analogs (known metabolites of filamentous fungi) and the optical isomer of a 
known metabolite (-)-rugulosin, along with (+)-deoxyluteoskyrin and (-)-skyrin which had 
not been previously described in literature.  
The effects of LPS in mammalian cells is well understood (Kim et al. 2004). LPS 
stimulates production of nitric oxide (NO) via inducible nitric oxide synthase iNOS. 
Schmidt ypothesized that this was also the driving factor behind improved and novel 
secondary metabolite production in the previously mentioned Penicillium species. To 
examine this hypothesis, light and fluorescence microscopy along with the NO scavenger 
c-PTIO were employed to examine the effects of induction with LPS on fungal and 
bacterial cells. These experiments showed that LPS alone induces fluorescence in 
Penicillium sp. (CMB-TF0411), which is quenched when LPS is co-administered with c-
PTIO. Strains that were less responsive to induction with LPS in terms of secondary 
metabolites were also not responsive in the fluorescent microscopy c-PTIO experiments. 
Schmidt et al.  postulated that this is due to the induction of a pseudo-inflammatory state 
by LPS, akin to what is seen in mammalian cells. Furthermore, they suggest an optimal 
stimulating concentration of LPS of 0.6 ng/mL for improved production of secondary 
metabolites in the form of three distinct responses: enhancement, activation, and 
acceleration. That is, increased yield, novel production, or lowered time of production, 
respectively. 
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Chapter 2. Results of Natural Product Experiments 
Section 1. General Growth and Induction Experiments 
PW2B as the Producing Strain of Berkeleylactone A 
 The Stierle Research Laboratory had previously identified PW2B (Penicillium 
clavigerum/camibertti) as the producing strain for berkeleylactone A and had also 
identified the CHCl3-broth extract of PW2A as being able to induce the production of 
berkeleylactone A in PW2B (Stierle et al. 2017). Because this demonstrates PW2B’s ability 
to express a diverse array of secondary metabolites, including those with antibiotic activity, 
it was used as the focus of my small molecule induced growths.  
 
 General Growth Protocol 
 The Stierle Lab has traditionally relied on Potato Dextrose Broth reconstituted with 
tap water for the growth of their extremophilic fungal strains. This helps provide 
micronutrients that might not be available in ddH2O. Growths were conducted in 500mL 
volumes to detect any initial activity, while providing enough material for the initial steps 
of purification. Each 1L of culture media was prepared as follows: 20g of complete Potato 
Dextrose Broth powder (Difco) was reconstituted in 1000 mL room temperature tap water 
in a 2000 mL large-mouth Erlenmeyer flask. This was then dispensed in 500mL portions 
into 1L large-mouth Erlenmeyer flasks, the tops were covered in aluminum foil, and the 
media was autoclaved. Once the media had cooled, it was inoculated with the fungus. The 
inoculum consisted of a piece of agar (1 – 3 mm2) from a mature 7-day solid culture 
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(sporulating) of the desired organism. The flask remained stationary for 1 hour to facilitate 
spore release and dispersal into the liquid medium. After one hour, cultures were grown at 
room temperature, 180 RPM for 24 hours. At 24 hours, 1 mL of HPLC-grade methanol 
was added to the inoculated culture media as an inducing agent. This addition utilized 
aseptic technique via the BSL-2 hood available to the Stierle lab and sterile pipette tips to 
avoid cross contamination. After induction, the growths were continued at 180 RPM, room 
temperature for 7 more days before processing.  
 
Bacterial Growths 
 E. coli (ATCC: 25922) and S. aureus (ATCC: 13709) cultures were inoculated from 
stock solutions provided by the Priestley Lab using aseptic technique in a BSL-2 tissue 
culture hood. Both E. coli and S. aureus were grown independently in 5 mL liquid LB (5g 
NaCl, 5g yeast extract, 10g peptone per 1L DI, autoclaved) cultures and on antibiotic-
selective agar plates. Liquid cultures were grown at 37oC, 120 rpm for 24 hours before use.  
 
PW2B Induction Experiments and Crude Samples 
 At time of harvest the pH of the broth was measured using litmus paper, and 
approximately 10 mL of methanol was added to each culture to wet the spores to curtail 
aerial dispersal during the harvest.  Next, the mature culture was gravity-filtered through 
filter paper, dried for 24 hours and then vacuum dried before a marc-weight was recorded.  
The filtrate was placed in a separatory funnel and thoroughly extracted with HPLC grade 
CHCl3 (3X). The resulting CHCl3 extract was dried via rotovap and transferred to a labeled, 
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tared 1-dram vial using CHCl3. The extract was dried under forced air and then in-vacuo 
for approximately 1 hour, and its mass (without a cap) was recorded (pg 23).  
 
Section 2. Purification, Characterization, and Activity Testing  
Bioassays and Si-flash/HPLC Purification 
Disk diffusion assays were conducted to assess initial activity against S. aureus and 
E. coli. This was done by loading 20 ug of crude extract dissolved in CHCl3 onto a sterile 
diffusion disk under a flame umbrella using sterile pipet tips. After drying for 
approximately 10 minutes near a Bunsen burner to ensure sterility, the disks were placed 
on agar plates of Difco Antibiotic Medium 2. The plates were incubated at 37oC for 24 
hours, at which point zones of inhibition around each disk were marked and measured.  
1 mg samples were prepared from both crude broth-CHCl3 extracts and HPLC 
fractions for antibiotic (Alamar Blue Assays) and protease inhibitor activity bioassays 
(caspase-1 and 3, mmp-3). The Alamar Blue Assay takes advantage of the REDOX of 
resazurin, and its ability to be reduced by cofactors such as NADPH, NADH, and 
cytochromes. These cofactors play crucial roles in cellular respiration, and reduction of 
resazurin by these cofactors is an indicator of cellular life and viability. The assay was 
conducted using a micro dilution approach based on Clinical and Laboratory Standards 
Institute standards for antimicrobial susceptibility (Performance Standards for 
Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals, 
5th Edition) utilizing clinically relevant MRSA, E. coli, Candida, and Bacillus strains 
available to the Priestley Lab.  
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Crude extracts with antibiotic activity, as identified by Alamar blue results and disk 
diffusions assays, were further purified using gravity column chromatography utilizing a 
silica gel stationary phase (Silica gel 60, 0.075 – 0.2 mm, S.A. 470-570 m2/g; Alfa Aesar). 
Crude extracts to be purified were dissolved in approximately 1 mL of CHCl3 and loaded 
onto a hexane-equilibrated Si-flash column. This extract was then eluted with an HPLC-
grade isopropyl alcohol (IPA) in HPLC-grade hexane step-wise gradient from 0% -> 100% 
(0, 5, 10, 20, 30, 50, and 100% IPA in Hex). Samples were collected for each corresponding 
solvent system. Approximately 1 mg of each crude extract was retained in case any issues 
arose during screening, or if additional material were needed for follow-up screening 
assays. Si-flash fractions were transferred to labeled clean 1-dram vials, and each column 
fraction with a mass > 1 mg was analyzed by 1H-nuclear magnetic resonance (NMR) in 
CDCl3 using a Bruker 400 MHz NMR with an autoloader. Further Alamar Blue assays 
were conducted on Si-flash fractions to determine antibiotic activity. Fractions with 
activity of ≤ 64 ug/mL against tested strains were subjected to high pressure liquid 
chromatography (HPLC) using either a methanol/CHCl3 or IPA/Hex stepwise gradient 
with a silica-gel column (Agilent Technologies Dynamax Microsorb 100-5 Si 10x250mm 
[DxL]). Pressure was maintained at or around 1,500 psi with a flow rate 2.5-3.5 mL/min 
while NMR and TLC were used to pool similar fractions. 1 mg samples from pooled-HPLC 
fractions were also prepared for signal transduction assays and antibiotic testing.  
 
NMR and LC-QTOF analysis 
 Samples were dissolved in CDCl3 for 
1H-NMR and 1 mg/mL samples were 
prepared in methanol and dispensed into mass spectrometry vials as mandated for use in 
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the robotic autoloader module for the Agilent Liquid Chromatography-Quantitative Time 
Of Flight (LC-QTOF) (Mass Spectroscopy Core, University of Montana). This allowed 
tracking of metabolites between experiments based on the presence or absence of 
molecular ion peaks corresponding to two previously identified secondary metabolites, 
gliovictin and hyalodendrin as they were the highest yield in the experiments discussed and 
had been previously identified in these cultures by the Stierles. For the LC-QTOF, the 
samples were solubilized in methanol, filtered through cotton, dried, re-massed, and 
resolubilized in equivalent amounts of methanol. This removed large particulate matter 
from the crude extracts which may damage the lines or pumps in the machine. This also 
ensured the final solutions were prepared at 1 mg/mL by accounting for any mass 
associated with large particulates that were filtered out of solution by the previously 
mentioned cotton filter. Utilizing a consistent concentration of crude extract for LC-QTOF 
analysis (1 mg/mL) allowed for relative comparisons of metabolite production between 
induction experiments. LC-QTOF was run on each crude extract using Stierle’s C18 
column (Phenomenex Gemini 3 um NX-C18 110Å LC-column 50 x 4.6 mm) on a 0.1% 
formic acid (Solvent A) to Acetonitrile (Solvent B) gradient in positive mode, utilizing the 
DonsLCFAfastposDI.m method (10uL injection volume, Dual ESI, 350 – 300 oC gas temp, 
Fragmentor: 210 V, 0.4 mL/min flow rate, DAD at 214 and 254 nm; 30% B to 100% B 
from 0 to 12 minutes, 100% B from 12 to 14 minutes, 100% B to 30% B from 14 to 14.1 
minutes, 30% B from 14.1 to 15 minutes). MassHunter Qualitative Analysis Software was 
used to identify weights of known compounds and track changes between experiments. 
This was accomplished by locating the masses corresponding to previously identified 
compounds from PW2B and letting the MassHunter software track peaks for those given 
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masses, while also providing an area for each identified peak. These were then overlaid on 
the initial LC-QTOF trace, providing a general profile for the tested fraction relative to 
known compounds. ACD Lab software was used for NMR visualization and peak picking 
to identify previously isolated compounds from the fractions based on chemical shift 
patterns characteristic to each metabolite. This was used to help attribute observed activity 
to compounds previously identified in PW2B that had known antibiotic activity. This was 
also used to track relative amounts of each known compound in analyzed samples to 
determine if any given induction technique increased expression of a known compound. 
 
Section 3. Results and Conclusions 
Results 
 Several compounds were used as inducing agents in liquid cultures of PW2B to 
evaluate their efficacy in the induction of new secondary metabolites production (Table 1, 
pg 23) Both bacterial lipopolysaccharide and methanol showed the ability to drastically 
change the secondary metabolome of P. clavigerum/camibertti (PW2B) to one that almost 
exclusively makes 2,5-diketopiperazines, including previously identified compounds 
gliovictin and hyalodendrin-S2. Of the agents used, it was determined that methanol yielded 
the best results with the most ease of use and fewest variables. This shows that induction 
of small molecules can be accomplished in extremophilic fungi. Because of this, the results 
section will focus on PW2B growths in 500 mL of PDB induced at 24 hours with methanol 
at a final culture concentration of 0.2%. These growths were done in triplicate, which were 
then compared to native PW2B cultures using LC-QTOF to access changes in secondary 
metabolite production as it related to CHCl3 crudes. These compounds were identified 
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using LC-QTOF (pg 25, 26, 27, 28) followed by 1D NMR techniques (pg 29, 30, 31, 32). 
Spectra were compared to standards provided by Dr. Donald Stierle who had identified 
these metabolites from earlier fermentation experiments. Crude samples were compared to 
samples of purified compounds during my time in the lab of Roquefortine C and 
Gliovictin/hyalodendrin. These comparisons utilized both LCMS and NMR (pg 28, 32). 
The production of hyalodendrin-S2 and hyalodendrin-S4 was associated with antibiotic 
activity (pg 24) in the crude fractions, as suggested in Michel et. al. 1973. Gliovictin and 
hyalodendrin were purified from crude fractions using an equilibrated gravity Si-flash 
column where the compound elutes in the 5-10% IPA in hexanes fractions, and a means of 
separating and crystallizing the hyalodendrin’s from gliovictin is discussed in detail in the 
paper by Michel from 1973. Roquefortine was easily isolated from crude fraction samples 
using an equilibrated gravity Si-flash column where the compound elutes in the 20-30% 
IPA in hexanes fractions. These two fractions were then pooled, dried, and purified via 
HPLC on a silica column under 5% methanol in CHCl3 to 10% methanol in CHCl3. Citrinin 
(a common isolate from PW2B extracts) was not identifiable in LCMS or NMR analysis. 
Citrinin is associated with a strong peak at 11 minutes utilizing the previously described 
LCMS protocol (pg 28). 
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Crude 
Fractions 
Inducer Solutions                                      
(final concentrations) 
Growth Volume pH 
Crude 
Mass      
(g) 
Marc 
Weight     
(g) 
km-1-66A 
E. coli in LB 
(250 uL of OD600 =~0.8) 
2x500 mL PDB n/a 0.0441 13.85 
km-1-66D 
Autoclaved E. coli in sterile 
DI  (250 uL of OD600 =~0.8) 
1x500 mL PDB n/a 0.0389 11.77 
km-2-135B 
6 ng/ml LPS in 500uL sterile 
DI H2O 
2x500 mL PDB 5 0.0013 13.46 
km-2-143B 
0.6 ng/ml LPS in 500uL sterile 
DI H2O 
2x500 mL PDB 7 0.0335 13.78 
km-2-3A 7.34 uM Asperfuran in MeOH  2x500 mL PDB 5 0.0484 15.16 
km-2-3B 30 uM Farnesol in MeOH  2x500 mL PDB 6 0.0529 20.6 
km-2-3C 30 uM Indole in MeOH  2x500 mL PDB 5 0.0445 14.85 
km-2-39B 1 mL of MeOH per 500 mL 2x500 mL PDB 5 0.0268 14.04 
km-3-6A Control 1x500 mL PDB 5 0.005 9.98 
km-3-6B Control 1x500 mL PDB 5 0.0038 10.26 
km-3-7B 1 mL of MeOH per 500 mL                 1x500 mL PDB 5 0.0066 9.87 
km-3-7C 1 mL of MeOH per 500 mL                   1x500 mL PDB 5 0.0057 10.87 
 
Table 1. General Growth Data. Basic growth data for induction experiments with 
PW2B. includes fraction names which corresponds to lab notebook number and pages, 
inducing agent used and concentration, growth volume and media used, pH of broth 
before extraction, mass of dried CHCl3-broth crude, marc weight, and a brief physical 
description of each biomass. All of the growth conditions produced beige nitballs. 
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Figure 2. RPLC-QTOF Data for Controls. (LC-QTOF) data of CHCl3-broth crude 
fractions of PW2B native (control) growths. (Top) Km-3-6A (Middle) km-3-6C and 
(Bottom) overlay of km-3-6A and km-3-6C. Samples were prepared in HPLC-grade 
methanol and run on a 30% ACN in 0.1% formic acid to 100% formic acid gradient, 
utilizing the method DonsLC-FA-fastposDI.m. Files were viewed using Agilent’s 
MassHunter Qualitative Analysis Software Package. 
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Figure 3. RPLC-QTOF Data for Methanol-Induced Fermentation Experiment. LC-
QTOF data of CHCl3-broth crude fractions of PW2B growths induced with 0.2% 
Methanol. (Top) Km-3-7B (Middle) Km-3-7C and (Bottom) overlay of km-3-7B with 
km-3-7C. Samples were prepared in HPLC-grade methanol and run on a 30% ACN in 
0.1% formic acid to 100% formic acid gradient, utilizing the method DonsLC-FA-
fastposDI.m. Files were viewed using Agilent’s MassHunter Qualitative Analysis 
Software Package. 
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Figure 5. RPLC-QTOF Data for Standards. LC-QTOF data of standards. (Top) 
Citrinin standard (Middle Top) Roquefortine C standard and (Middle Bottom) 
Gliovictin standard. Samples were prepared in HPLC-grade methanol and run on a 30% 
ACN in 0.1% formic acid to 100% formic acid gradient, utilizing the method DonsLC-
FA-fastposDI.m. Files were viewed using Agilent’s MassHunter Qualitative Analysis 
Software Package. (Bottom) Structure of Citrinin (https://en.wikipedia.org/wiki/Citrinin) 
11.0 minutes  
m/z = 233 
1.35 minutes  
m/z = 390 
5.38 minutes  
m/z = 377 
6.9 minutes  
m/z = 354 
(weak overall peak) 
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Figure 6. 1H-NMR Data for Controls1H-NMR data of CHCl3-broth crude fractions for 
PW2B native (control) growths. (Top) Km-3-6A (Middle) km-3-6C and (Bottom) 
overlay of Km-3-6let series. Samples were all prepared in 99.8% deuterated chloroform 
and scanned with a Varian 500MHz NMR. Files were viewed using ACD 1D NMR 
Processor software. 
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Figure 7. 1H-NMR Data for Induced. 1H-NMR data of CHCl3-crude fractions for 
PW2B growths induced with 0.2% HPLC-Grade Methanol. (Top) Km-3-7B (Top 
Middle) km-3-7C (Bottom Middle) km-2-39B and (Bottom) overlay of Km-3-67let 
series and km-2-39B. Samples were all prepared in 99.8% deuterated chloroform and 
scanned with a Varian 500MHz NMR. Files were viewed using ACD 1D NMR Processor 
software. 
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Figure 9. 1H-NMR Data for Controls1H-NMR data of standards. (Top) Citrinin 
standard (Middle) Roquefortine C standard and (Bottom) Gliovictin standard. Samples 
were all prepared in 99.8% deuterated chloroform and scanned with a Varian 500MHz 
NMR. Files were viewed using ACD 1D NMR Processor software. 
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Furthermore, induction with E. coli produces a similar secondary metabolite profile 
to that of growths induced with LPS at either 0.6 ng/mL or 6 ng/mL in Potato Dextrose 
Broth, where 6 ng/mL proved deleterious to overall secondary metabolite production in 
PW2B while 0.6 ng/mL showed a more familiar crude mass (pg 23). Indole was also tested 
as it is the largest yield secondary metabolite from E. coli, but these experiments proved 
inconclusive due to the presence of methanol as a solvent. Later experiments with methanol 
alone (km-2-39B, km-3-7letter) suggested that this metabolic shift was due to the effects 
of the solvent, and not the small molecules dissolved in the solvent. This was shown by the 
km-2-3letter series and the km-3-7 letter series, where each had near identical biological 
activities despite them all being induced with different small molecules dissolved in 
methanol (km-2-3letter) or induced with just methanol (km-3-7letter).  
In total, methanol induction provided several drastic changes, as evident by LC-
QTOF and 1H-NMR analysis (pg 27, 31). For LC-QTOF, induced fractions (7B, 7C) both 
have a signal at 5.83 minutes with a parent ion at m/z = 377, which represents the M+Na 
(354+23) adduct for gliovictin. Furthermore, a peak at 7.375 minutes consists of a parent 
ion peak of m/z = 347 and 283, which represents the M+Na and M-S2+Na peak for 
hylaodendrin-S2. When these samples were analyzed via NMR, it was apparent that these 
2 compounds made up the large majority of the crude fractions for km-3-7B and km-3-7C. 
Both of these peaks and masses were undetectable in control samples km-3-6A and km-3-
6C. It is also worth noting that the control fractions have a peak at 9.50 minutes, 
corresponding to the mass of an unknown compound with an m/z = 509. All samples also 
show a peak at 1.35 minutes representing a parent ion of m/z = 390, which was isolated 
and found to be Roquefortine C. 
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Conclusions and Future Directions 
 Growth and induction of P. clavigerum/camiberti PW2B with the described 
methods produced some interesting results. It was successful in that induction with 
methanol provoked a response that involved drastic, reproducible changes to the secondary 
metabolome of PW2B. These changes were also associated with antibiotic activity which 
was ascribed to a series of known 2,5-DKPs, which suggests the induction of BGCs 
containing NRPSs. Epipolythio-dioxopiperazines (ETPs) are a common class of 2,5-DKP 
secondary metabolites formed via NRPSs that contain a 2, 4 or 6 sulfur bridge between 
alpha carbons on the piperazine ring, and include hylaodendrin-S2, S4, and gliovictin.  In 
the publication by Gardiner et. Al from 2005, it is noted that epipolythio-dioxopiperazines 
are capable of general protein inactivation and REDOX cycling. These 2 functions help to 
fight off competing microbes, potentially reducing the oxidative stress imparted on the 
producer strain by the environment. This is further exemplified by the broad-spectrum 
antibiotic activity of hyalodendrin-S2 and S4 against gram-positive and gram-negative 
bacteria and some yeast species.  
The impacts of oxidative stress on secondary metabolite production has been 
previously observed in several publications (Roze et al 2011; Yin et al. 2013). Due to the 
generalized nature of oxidative stress generation, a generalized response is required from 
an organism to help control its environment. Furthermore, methanol inducible promoters 
have been identified in the model organism Pichia pastoris (Wang et al. 2016). This 
alcohol oxidase promoter (PAOX1) is involved in the metabolism of methanol and has been 
utilized for large scale protein production, like that of the lac operon utilized in Invitrogen’s 
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GATEWAY recombination system. While there is no evidence for the presence of this 
specific promoter, induction experiments with PW2B and methanol suggests a similar 
mechanism might be in play for the production of 2,5-DKPs and the expression of NRPSs, 
specifically for gliovictin and the hyalodendrins. 
 Future efforts in this project could be directed down a number of routes for 
verification that induction of non-ribosomal peptide synthases is in fact occurring. This 
would include sequencing the full PW2B genome. This sequence would then be subjected 
to any number of bioinformatic programs/approaches to identifying either the appropriate 
gene cluster (SMURF, antiSMASH, NRPSPredictor, NP.Searcher; Suzuki et al. 2001; 
Khaldi 2010; Medema et al 2011; Blin et al 2017), focusing on the gliovictin BGC, or for 
the appropriate promoter (PePPER; de Jong et al 2012), focusing on the PAOX1 promoter 
(Shi et al 2018). The alternative to this would be using strict molecular biology to isolate 
the DNA of PW2B, and subject it to a number of PCR reactions to try to identify if PAOX1 
or if a PAOX1-like promoter exists in PW2B.   
 
Chapter 3. Introduction to Protein Crystallography and Drug Design 
Section 1. Rational Small Molecule Design 
Semisynthetics 
While the case for natural products in therapeutics has historically made itself, the 
need for more potent and safer compounds is always of interest. Also, continued analog 
development is always of interest to pharmaceutical companies in search for larger drug 
libraries in the pursuit of continued profits and increased marketability. More recently, this 
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has been approached utilizing rational drug design. This is exemplified by the acetylation 
of salicylic acid to acetylsalicylic acid (Aspirin) by Felix Hofmann, which reduced the 
unpleasant gastrointestinal side effects of salicylic acid when taken orally. Aspirin is 
therefore classified as a semisyntheti drug, a natural product that was modified to produce 
an analog with improved activity and/or reduced toxicity. This approach has provided a 
variety of useful compounds, two of which I will focus on shortly: avermectin analogs and 
vancomycin analogs. These examples, along with that of aspirin show the utility of 
combining natural products with rational drug design. 
Streptomyces avermitilis was discovered in the early 1970s by Satoshi Omura at 
the Kitasato University from a soil sample in Tokyo, Japan. Dr. Omura subsequently 
identified the culture as having antiparasitic activity. After a culture sample was supplied 
to Dr. William Campbell at Merck in 1973, avermectin was isolated from fermentation 
broths and identified as the active component. Through derivatization efforts led by 
William Campbell, Ivermectin was synthesized with lowered toxicity and improved 
activity via reduction of a single double bond outside of the larger macrocyclic ring. 
Ivermectin was generated through a trial and error process of generating analogs, screening 
them in an assay, and then comparing activity profiles of each analog. While this is one of 
the approaches for rational drug design, there are other routes that have been utilized for 
analog development.  
 (https://www.acs.org/content/acs/en/education/whatischemistry/landmarks/ivermectin-
mectizan.html) 
If the mechanism of action of a compound is known and well-characterized, then a 
guided approach to small molecule drug design can be employed, as shown by vancomycin 
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analog generation. Vancomycin is a clinically used glycoprotein antibiotic whose 
producing organism was originally identified by Edmund Kornfeld at Eli-Lily in 1953. It 
was produced by an organism (Streptomyces orientalis) isolated from a soil sample from 
Borneo (Griffith, 1981). Vancomycin works by binding to the incoming NAG-NAM-
Peptide sections of the forming cell wall in gram (+) bacteria. Normally, the peptide tails 
contain 2 terminal D-ala-D-ala residues at a fork in the peptide chain with a repeat of 
glycine residues that will be clipped during the cell-wall formation process. Vancomycin 
works by binding these D-ala-D-ala residues via peptide backbone interactions (Schäfer et 
al. 1996). Resistance to Vancomycin is induced when the terminal D-alanine is converted 
to D-lactate, eliminating a key hydrogen bond interaction between the amide proton of the 
alanine and vancomycin itself.   
In an attempt to generate analogs that could overcome vancomycin-resistance in 
pathogenic bacteria, Xie et. al in 2011 developed a series of vancomycin-aglycon 
[ψ[C(=NH)NH]Tpg4] analogs that conversely swapped its hydrogen-bond acceptor for a 
hydrogen-bond donor, to match the backbone change of an amide in D-ala-D-ala (wild type 
bacteria) to the ester in D-ala-D-lac (resistant bacteria). One of these analogs was reported 
to have 1000-fold improved potency over vancomycin-resistant enterococcus (E. faecalis) 
and is one of several analogs that attempt to combat the D-ala to D-lac mutant. Although 
none of these analogs are used clinically, this work demonstrates the utility of applying a 
structurally-directed approach to drug design from natural products.  
These examples illustrate the utility of synthetic modification after the 
identification of bioactive secondary metabolites. In the case of ivermectin it was an 
iterative process of making a single modification to a compound and testing the activity of 
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the resulting analog. Once a sufficient number of analogs were generated and tested, a 
structure activity relationship (SAR) could be generated for the compound class, and 
rational drug design could begin.  
Vancomycin, on the other hand, represents a much more complicated story due to 
its 3-dimensional structure that acts as a cap to the peptide-tail target (Sheldrick et al 1996 
and Xie et al. 2012, Okana et al 2017). Generating a simple 2D SAR for vancomycin would 
be significantly less effective in analog design when compared to a 3D representation. This 
3D SAR can be assembled using small molecule and protein crystallography which 
provides detailed information on stable small molecule or ligand-protein conformers. This 
information can then be used computationally to direct analog development in silico 
through the application of Monte-Carlos docking simulations (Melvin 2012; Leelananda 
and Lindert 2016).  
 
History of Protein Crystallography 
Protein crystallography with bound ligands allows for an accurate 3D map to be 
assembled for a ligand and its protein target, which is useful knowledge to have in rational 
drug design. The history of protein crystallography begins early in the 1900s with the initial 
discovery that X-rays are diffracted by crystals and by the observations of William Bragg 
and his son Lawrence Bragg in 1913 (Bragg et al 1913). With the formulation of the Bragg 
equation, a process was developed to assemble 3D structures from the Bragg reflections, 
the pattern of dots that are produced on the receiver side of an x-ray diffractor. This allows 
for spatial and angular measurements to be made between the atoms that produced each 
Bragg spot. When applied to protein crystals, x-ray diffraction can provide a detailed map 
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of the target with theoretical resolutions of up to 1 Å.  Sir John Kendrew generated the 
structure of myoglobin, which was the first protein to be crystallized and its structure 
determined, for which he and Max Peruitz were awarded a Nobel Prize in Chemistry in 
1962 (Kendrew et al. 1958). Although this marked the beginning of x-ray crystallography 
of proteins, the technique would not be used successfully for structure-based drug design 
until the 1990s where crystal structures were used in modeling (Carrillo et al. 1990, Roberts 
et al 1990) and in cocrystallization experiments for analog design (Ghosh et al. 2007). 
These structure-based strategies have been used to identify potential peptide-backbone 
interactions with HIV protease. This information was then used to modify a compound 
derived from structure-based drug design (Darunavir; Ghosh 2007; 2015) into even more 
potent analogs.   
There are a number of clinically used small molecules generated through the use of 
structure-based drug design. As stated by Rob van Montfort and his colleagues in his 
publication from 2017, “As we write, FBDD (fragment-based drug design [a subset of 
structure-based drug design]) has yielded over 30 clinical drug candidates and also three 
FDA-approved drugs in oncology: the BRAF inhibitor vemurafenib, the BCL-2 inhibitor 
venetoclax, and the CDK4 inhibitor ribociclib.” (van Montfort and Workman, 2017). Drugs 
developed with the assistance of SBDD also include Imantinib (BCR-abl inhibitor), 
Dorzolamide (carbonic anhydrase inhibitor) and Boceprevir (NS3 protease inhibitor) and 
Darunavir (HIV protease inhibitor) (Ghosh et al 2007; Murray and Reese, 2009; Howe et 
al 2013; Jaskolski et al 2014; Blundell 2017; van Montfort and Workman, 2017).   
This high definition structural data can be used to help further understand (1) the 
mechanism of action for a particular ligand, (Suguna et al 1987; Esnouf et al 1995) (2) to 
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establish a network of interactions responsible for the ligand-protein association, (Mittl et 
al 1997) (3) provide a negative template for the generation of novel structures (Ghosh et al 
2007, 2015; Howe et al 2013), and (4) provide insight into ligand selectivity between two 
target proteins (Guzik et al. 2017). Structure-based drug design represents a rational way 
to design higher affinity analogs while providing structural information on important 
chemical motifs, which relies heavily on protein crystal structures. These 3D structures 
then can be optimized for either protein binding, for identifying motifs not involved with 
the protein-ligand interaction, and for SARs to be established (Melvin 2012; Leelananda 
and Lindert 2016). Structural characteristics can be used for identification of sites for 
modification to help improve selectivity, reduce toxicity, or improve the pharmacokinetic 
profile of future analogs (Guzik et al. 2017). While these structures only represent the most 
stable conformers of the protein and ligand that allow for crystallization, the level of detail 
provided is unmatched with any non-diffractive technique. This detail can help provide 
direct information on analog development, as it had with Imantinib, Darunavir, Boceprevir, 
and other previously mentioned clinically relevant compounds (Murray and Reese, 2009; 
Howe et al 2013; Jaskolski et al 2014; Zheng et al 2014; Bundell 2017; van Montfort and 
Workman, 2017).  
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Section 2.  Caspase-1 and -3 in Protein-Based Small Molecule Design:  
Caspase-1 and Inflammation 
 For over twenty years the Stierle research laboratory has utilized the inhibition of 
specific signaling enzymes as a tool for drug discovery.   They use caspase-1 inhibition 
assays (Enzo) to guide the isolation of caspase-1 inhibitors from complex fungal extracts. 
Caspase-1 is an important component of inflammation in mammalian cells, and 
dysregulated inflammation is associated with many different pathologies. Inflammation is 
a tightly regulated immunological process mediated by several gene products and 
physiological cell responses. This initially manifests in the maturation of interleukin-1β 
(IL-1β) via cleavage by caspase-1. Inflammation is initiated when a macrophage is exposed 
to a damage or pathogen associated recognition pattern, DAMPs and PAMPs, respectively. 
These are remnants of either viruses, pathogenic bacteria or dead neighboring cells, and 
include carbohydrates, LPS, dsDNA, ssDNA, and RNA.  
In mammalian cells the initial response leads to the production of pro-caspase-1 
and pro-IL-1β. Caspase-1 is cleaved from its p30 zymogen to an active p10/p20 
heterodimer and is then assembled into the inflammasome. This macromolecular circular 
heterotrimer protein complex is similar in structure to the apoptosome with which caspase-
3 is involved. Once the inflammasome is assembled, caspase-1 cleaves IL-1β, which exits 
the cell to further provoke the COX-1/2 mediated part of inflammation.  
In theory, if you mitigate the activity of caspase-1 you can block inflammation at 
the source, which could have implications in autoimmune diseases, pain management, 
stroke, and cancer (MacKenzie et al. 2010). The Stierle lab has isolated and characterized 
several caspase-1 inhibitors from Berkeley Pit fungi.  These active enzyme inhibitors were 
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then evaluated in the induced macrophage assay to assess their ability to mitigate 
production of proinflammatory cytokines in a cell-based reporter system. 
 
 
Caspase-3 and Apoptosis 
 The Stierle laboratory also looks for novel small molecule inhibitors of caspase-3 
(Stierle et al 2014). Caspases play several roles in apoptosis, with all pathways leading to 
the activation and action of caspase-3. This includes the intrinsic and extrinsic pathways 
involving caspase-9 and 8 directly upstream from caspase-3. Like caspase-1, caspase-3 is 
initially expressed as a p30 zymogen which is cleaved to p13/p17 in vivo by caspases 8 or 
9. Caspase-3 is also capable of auto-proteolysis meaning caspase-3 can self-activate itself 
in vitro when purified. Caspase-3 specifically targets the peptide sequence XAXD-X 
(Thornberry et. Al 1997) and it’s been suggested that caspase-3 has upwards of 600 
substrates, indicative of its role in apoptosis.  
Elevated levels of caspase-3 have been shown in Alzheimer’s disease, autoimmune 
diseases, and stroke. (Su et al. 2001; Ahmed et al. 2002; Wanger et al. 2011; Fan et al. 
2014).  Of importance is its role following stroke and traumatic brain injury (Manabat et 
al. 2003; Fan et al. 2014). Elevated levels in the penumbral region surrounding the infarct 
zone lead to extensive damage beyond the site of the initial insult.  The Stierles also use a 
caspase-3 inhibition assay to find compound that could mitigate this post-stroke damage. 
Given the drastic nature of apoptosis, regulation and dysregulation can play a 
crucial role in the developing body and in developing tumors. Given the roles of the 
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caspases in autoimmune disease, development, cancer, and inflammation, both caspase-1 
and caspase-3 represent useful targets for the realm of structure-based drug design 
(MacKenzie et al. 2010). 
 
Section 3. Caspases: Structure 
The Caspases: General Structure 
 The caspase (cysteine-aspartate protease) family of proteins gets its name from its 
active residue and its target peptide. The caspase family exists as a heterodimer of a large, 
catalytically active, 20 kDa, p20 subunit and a smaller, 10 kDa, p10 subunit both expressed 
as a singular procaspase zymogen. Generally, the caspases are approximately 30 kDa, 
cytosolic proteases consisting of 6 β-sheets surrounded by five α-helices. The caspases 
utilize a nucleophilic cysteine moiety on the large p20 subunit that attacks an amide 
carbonyl carbon. The subsequent oxy-anion is stabilized by a neighboring histidine residue 
in the P1 aspartate binding pocket approximately 6Å away (Fang et al 2006). 
 
The Caspases: Ligand Binding Cleft  
While the specific substrates targeted can vary for the 14 identified caspases, the 
structure of the caspase active site, which is made up of loops 1-4, can be described in some 
more general terms with respect to the S1 and S2 sites (Fang et al 2006). This is shown 
graphically in Fig. 2 where Ac-DEVD-CHO (Ligand) is extending from the S1 (right) to 
the S4 (far left) binding sites on caspase-3. The ligand binding cleft for the caspase family 
proteins is a long trough shaped pocket capable of stabilizing 4 amino acid residues prior 
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to cleavage. The S1 binding pocket gives the caspase-family its aspartate-selectivity, while 
the three remaining sites provide further ligand-sequence selectivity. This pocket is at the 
p10/p20 interface with the active cysteine at the top and its partner histidine located on the 
opposite side, approximately 1/3 of the way from the rim of the hole, both of which are on 
the p20 chain. The S1 hole is approximately 8 Å deep and utilizes an Arginine at its bottom 
to stabilize the aspartate sidechain on the native ligand. The S2 binding site on the caspases 
are a generally hydrophobic site that stabilizes lipophilic P2 sidechain of the native ligand 
(pg 46). For caspase-3, this involves a phenylalanine residue, a tryptophan residue and a 
tyrosine residue, providing a large hydrophobic pocket for caspase-3 preferred P2 residue, 
valine. 
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Figure 11. Caspase-3 Crystal Screen Captures. (Top) General schematic for protease 
active sites. (Hook et al. 2015) (Left) Image capture of caspase-3 positive control using 
Pymol. Qualitative electrostatic potential map of caspase-3 with a stick model of Ac-
DEVD-CHO. This further illustrates the S1 to S4 sites (right to left) represented in loops 
1-4. (Right) Stick and ribbon representation of caspase-3 S1 and S2 sites bound to Ac-
DEVD-CHO. This shows the lipophilic S2 site with the flanking tyrosine, tryptophan, 
and phenylalanine residues and the charged S1 site with the active cysteine, arginine, and 
histidine. 
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Chapter 4. Protein Expression and Crystallography 
Section 1. Caspase-1 Methods and Materials 
GATEWAY Recombinant Technology and Primer Design 
 Invitrogen’s GATEWAY Recombinant Technology allows for simplistic 
vectorization and amplification of targeted genes for expression in bacterial, insect, or 
mammalian cells. This relies on a flanking primer region that gets added to your target 
DNA sequence via PCR, which is subsequently used to ligate this modified DNA into a 
species-specific plasmid. This allows for simple protein induction in a variety of cell types, 
with expression in E. coli utilizing a lac promoter which can be induced using iso-propyl 
thiogylactopyranoside (IPTG). 
 The process involves 2 classic PCR experiments because the size of the primers 
involved exceed the suggested limit of around 38 bases. This results in a DNA sequence 
tagged as designed, with the attB-flanking sequence and any built-in tags on the chosen 
pDEST vector. The next step involved a BP-clonase reaction where an attB-flanked 
sequence was transferred into a pDONR donor vector via a protein mixture named BP 
Clonase. After the BP reaction, the plasmid was amplified using DH5a E. coli cells. The 
final step involved transferring my sequence from the plasmid donor into a vector sequence 
using a 1-hour LR reaction, similar in nature to the BP reaction. PCR and amplification 
steps were followed by DNA purification using a QIAprep MINIprep column and the 
absorbance at 260 nm was used to record the corresponding nucleic acid concentration.  
This plasmid was then sequenced, and used to transform BL21 DE3 pLysS E. coli, 
in this case. The transformation protocol is as follows: 50uL of competent cells were placed 
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on ice, to which 4uL of plasmid was added. This solution was incubated on ice for 20 
minutes, followed by 45 seconds in a 42oC water bath, and an additional 2 minutes on ice. 
450uL of LB was added aseptically to the tube, which was then incubated at 37oC, 180rpm 
for 1 hour. 100uL of this solution was plated on an Amp+ LB plate overnight at 37oC, and 
colonies were picked the next day for further processing.  
Because the pDEST vectors have Ampicillin and Chloramphenicol resistance 
sequences and the pDONR provides kanamycin resistance, either can be used for 
amplification and transformation selection, as appropriate. BL21 DE3 pLysS E. coli are 
super competent E. coli engineered to contain both a DE3 lysogen and pLysS plasmids. 
These plasmids help reduce basal gene expression by utilizing a T7 RNA polymerase 
(DE3) with a T7 lysozyme (pLysS) and are often employed when the native function of 
the expressed protein might be toxic or deleterious to cell function. DH5a cells are also a 
super competent E. coli strain used for plasmid amplification. 
 
Caspase-1 Expression and Validation 
Based on previously published methodologies (Wilson et al. 1994; Garcia-Calvo et 
al. 1997; Romanowski et al. 2005; Roschitzki-Voser et al. 2012), caspase-1 was expressed 
as two independent peptides (p10 and p20) that were combined during refolding 
experiments after initial purification on a grav-flow Ni-NTA column, relying on the 
inserted 6xHis tag.  
Caspase-1 DNA was ordered from GenScript based on the NCBI reference 
NM_033292, which was used as the target sequence for BLAST verification after the 
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GATEWAY LR reactions. This ensured that the target vector was loaded with the target 
peptide sequence. Caspase-1 p10 and p20 primers were designed based on this sequence 
with a TEV-protease C-terminal domain and the added GATEWAY flaking sequences as 
described in the GATEWAY protocol, focusing on residues 307-407 and 120-297, 
respectively (pg 50). A pDEST17 vector was used which added C-terminal 6xHis tags onto 
the target peptide directly, which meant that the 6xHis sequence did not need to be designed 
into the primers. 
First, caspase-1 DNA was dissolved in 20uL of DNAase free water. The DNA was 
amplified via the described transformation procedure using DH5a E. coli cells, and 
subsequently grown on an Ampicillin+ LB agar plate at 37oC. The next day a single colony 
was picked using aseptic technique and grown overnight in 10mL SOC broth with 
ampicillin, 37oC, 180 rpm; this was done in duplicate. The following day the 10mL growths 
were pelleted at 4,000 rpm for 10 minutes. The supernatants were removed, and the pellets 
were processed using a QIAprep MINIprep kit. Nanodrop was done to validate 
amplification, with a value at 434.4 and 623.3 ng/uL.  
This DNA was then subjected to the GATEWAY recombination process beginning 
with the PCR#1 protocol for both caspase-1 p10 and p20 independently. The primers, 
thermocycle runs, and cleaned product concentrations for the caspase-1 GATEWAY 
protocol are described on the following page.   
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Caspase-1 p20 Primers (Res 120-297) 
Forward Primer #2: 
TEV-CASP1-120  
5’-GAA-AAC-TTA-TAT-TTT-CAG-GGT-AAC-CCA-GCT-ATG-CCC-ACA-TCC-3’ 
Underlined sections overlap with forward primers. 
Flanking region portion is in bold. 
 
Forward Primer #1: 
ATTB-TEV 
5’-GGGG-ACA-AGT-TTG-TAC-AAA-AAA-GCA-GGC-TTC-GAA-AAC-TTA-TAT-TTT-
CAG-3’ 
Flanking region portion is in bold. 
 
Reverse Primer #1 and #2: 
ATTB-CASP1-297  
5’-GGGG-AC-CAC-TTT-GTA-CAA-GAA-AGC-TGG-GTC-CTA-ATC-TTT-AAA-CCA-
CAC -3’ 
Flanking region portion is in bold.     
 
                             
Caspase-1 p10 Primers (Res 317-404) 
Forward Primer #1: 
TEV-CASP1-317  
5’-GAA-AAC-TTA-TAT-TTT-CAG-GGT-GCT-ATT-AAG-AAA-GCC-CAC-ATA -3’ 
Underlined sections overlap with forward primers. 
Flanking region portion is in bold. 
 
Forward Primer #2: 
ATTB-TEV 
5’-GGGG-ACA-AGT-TTG-TAC-AAA-AAA-GCA-GGC-TTC-GAA-AAC-TTA-TAT-TTT-
CAG-3’ 
Flanking region portion is in bold. 
 
Reverse Primer #1 and #2: 
ATTB-STOP-CASPASE1-404 
5’-GGGG-AC-CAC-TTT-GTA-CAA-GAA-AGC-TGG-GTC-CTA-ATG-TCC-TGG-GAA-
GAG-3’ 
Flanking region portion is in bold.     
 
 
Table 3. Caspase-1 Primers. Caspase-1 primers for subunit p20 (residues 120-297) and 
p10 (residues 317-404) used in the GATEWAY recombination process. Bold regions 
denote flanking attaB sequence. Underlined regions show primer overlap for construct 
extension. 
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DNA amplification: 
1. DNA dissolved in 20ul DNAse free water 
2. 2 uL added to 50ul of DH5a 
3. On ice, 20 minutes 
4. 42oC water for 45 seconds 
5. Ice for 2 minutes 
6. Add 450 ul LB w/o antibiotic 
7. 1 hour, 37oC 
8. Spread 100ul of cells on amp+ LB plate 
9. O/N growth at 37oC 
10. Pick into 10 ml SOC o/n 37oC 180rpm 
11. Grow ON 
12. Miniprep and nanodrop 
 
PCR #1 (flanking region) 
1. 1uL DNA (434ng/uL)  
2. 1uL fPrimer or f-attb-TEV 
3. 1uL rPrimer or r-attb-TEV 
4. 1uL dNTP 
5. 5uL 10X buffer 
6. 41 uL sterile H2O 
7. 1uL Taq *add last* 
Spin 30s to mix 
 
PCR #2 (attb-TEV) 
1. 1-2uL PCR product (need ~90ng total) 
2. 1uL f-attb-TEV 
3. 1uL r-attb-TEV 
4. 1uL dNTP 
5. 5uL 10X buffer 
6. 41 uL sterile H2O 
7. 1uL Taq *add last* 
8. Spin 30s to mix 
 
 
 
BP rxn 
1. 1-10uL attb PCR product (40-100fmol) 
2. 2uL pDONR (150ng/ul) 
3. 2uL 5x BP Clonase Rxn Buffer 
4. TE buffer pH 8 to total volume of 10uL 
5. Incubate 25oC 1 hour 
6. Add 2uL of Proteinase K 
7. Incubate 10 mins 37oC 
8. Transform DH5a on kanamycin+ plates 
 
LR rxn 
1. Add volume for 120-160ng BP product 
2. Add pDEST vector in equivalence to BP 
product 
3. TE buffer to 6uL 
4. 2uL 5x LR clonase *add last* 
5. Transform onto DH5a 
 
Thermocycler: 
1. 94oC 5 min 
2. 94oC 30s 
3. 54oC 45s 
4. 72oC 2:30 
Repeat 35 times 
5. 72oC 10 min 
6. 4oC O/N 
Validate w/ nanodrop 
 
Table 4. Transformation Protocol. Protocol for GATEWAY recombination PCR 
reactions along with thermocycler temperature and reaction times. 
https://www.thermofisher.com/us/en/home/life-science/cloning/gateway-
cloning/gateway-technology.html 
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The p10 (residues 317-404) and p20 (residues 120-197) plasmids were used to 
transform two separate batches of BL21 DE3 PLysS cells, which were subsequently grown 
on Amp+/ LB plates. After overnight incubation at 37oC, single colonies from each plate 
were picked and used to inoculate separate 50mL LB growths, which were grown at 37oC, 
200 RPM overnight. These were used to inoculate two separate 6 x 1L batches of 2xYT 
(16g Tryptone, 10g Yeast extract, 5g NaCl, pH 7.0) growths containing 100 mg/L 
Ampicillin (final concentration, added during E. coli inoculation of media), which were 
then grown at 37oC and 200 RPM for ~4 hours. Log phase growth was tracked using the 
OD600nm and a spectrophotometer. Once OD600nm ≈ 0.6, the cultures were induced with 1 
mM IPTG (final concentration). Once induced, the culture temperature was dropped to 
30oC, and the cells were grown at 30oC 200 RPM, overnight. 
The next day, cells were harvested and centrifuged at 7,000 RPM, 4oC, for 35 
minutes. The pellets were collected and homogenized with Lysis Buffer (50 mM Tris pH 
8.0 and 300 mM NaCl, filtered at 0.2 um) using a hand blender. The homogenate was then 
centrifuged at 35,000 RPM, 4oC, for 35 minutes. The pellets were then collected and 
homogenized with Wash Buffer (50 mM Tris pH 8.0, 300 mM NaCl, and 1M Guanidine-
HCl, filtered at 0.2 um) using a dounce on ice. The homogenates were again centrifuged at 
35,000 RPM, 4oC, for 35 minutes. This washing process was repeated twice. 
The pellets were collected and homogenized with Solubilizing Buffer (20 mM DTT 
and 6M Guanidine-HCl, filtered at 0.2 um). Homogenates were again centrifuged using a 
floor mounted centrifuge at 35,000 RPM, 4oC, for 35 minutes. The supernatants were 
collected, and an SDS-PAGE was run to verify the location of p10 or p20, respectfully, in 
the solubilizing buffer. 
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Figure 12. Caspase-1 SDS-PAGE. SDS-PAGE of caspase-1 p10-p20 solution in 
denaturing buffer. Gel was stained using Coomassie Brilliant Blue. Image depicts bands 
at approximately 20kDa and 10kDA, along with a kaleidoscope ladder on the right 
(Biorad). 
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Caspase-1 Refolding 
 Because caspase-1 subunits are expressed in insoluble-inclusion bodies, 
denaturation of the subunits was conducted independently and subsequent refolding 
experiments were conducted on the subunits in a 2:1 p10:p20 ratio by volume, respectively. 
This approach employed methodologies that had been previously reported for caspase-1 
refolding (Scheer and Romanowski et Al. 2004, pg 55).  
The p10 and p20 subunits in Solubilizing Buffer were concentrated to ~4 mg/mL 
and mixed in a 2:1 ratio by volume. 1 mL of the mixture was added to 50 mL Refolding 
Buffer (50 mM HEPEs pH 8.0, 100 mM NaCl, 1 M NDSB-201, and 20 mM DTT, filtered 
at 0.2 um) by several methods as listed on the next page. Rapid dilution entails adding the 
2:1 mixture directly to the refolding mixture, bag dialysis employs bag dialysis tubing, 
while a Slide-a-lyzer is a specific dialysis tool involving a cassette and a dialysis 
membrane, which is floated in dialysis buffer. In general, this mixture was stirred for 3-8 
hours at 4oC or room temperature and then centrifuged using a floor mounted centrifuge at 
35,000 RPM, 4oC, for 35 minutes. Visual inspection for precipitate before centrifugation 
and nanodrop assays after centrifugation were used to quantitate any soluble protein after 
refolding. 
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Method Refolding Buffer Publication 
Rapid Dilution, 
RT, 4 hours 
50mM HEPEs pH 8, 100mM NaCl, 
20mM DTT, 1M NDSB-201, 100mM 
Sodium Malonate 
Romanowski et Al., 2004                   
Garcia-Calvo et Al. 1999 
Rapid Dilution, 
4oC, 8 hours 
50mM HEPEs pH 8, 100mM NaCl, 
20mM DTT, 1M NDSB-201 
Romanowski et Al., 2004 
Rapid Dilution, 
4oC, 4 hours 
50mM HEPEs pH 8, 100mM NaCl, 
20mM DTT, 1M NDSB-201 
Modified Romanowski et Al., 2004 
Rapid Dilution, 
RT, 8 hours 
50mM HEPEs pH 8, 100mM NaCl, 
20mM DTT, 0.1 to 1.0% NP-40 
Modified Rano et Al. 1997 
Rapid Dilution, 
RT, 8 hours 
50mM HEPEs pH 8, 100mM NaCl, 
20mM DTT, 0.05 to 0.2% CHAPs 
Rano et Al., 1997                  
Slide-a-lyzer,    
RT, 4 hours 
50mM HEPEs pH 8, 100mM NaCl, 
20mM DTT, 1M NDSB-201 
Modified Romanowski et Al., 2004 
Bag Dialysis, 
4oC, 8 hours 
50mM HEPEs pH 8, 100mM NaCl, 
20mM DTT, 1M NDSB-201 
Modified Romanowski et Al., 2004 
Bag Dialysis, 
4oC, 8 hours 
50mM Sodium Acetate pH 5.9, 
100mM NaCl, 15% glycerol, 4 mM 
DTT 
Roschitzki-Voser, Grutter, et Al., 2012 
 
Table 5. Caspase-1 Refolding Conditions. Refolding conditions explored for caspase-1 
p10-p20 solution. Progress was followed using nanodrop and SDS-PAGE. Includes 
publications that provided references for refolding conditions, and if they were modified 
or not. 
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Conclusions and Future Directions 
 Protein refolding represents an extremely complicated process, to which a solution 
may not be trivial. While I was able to explore several techniques that had previously been 
published for the refolding of caspase-1 subunits together to form an active caspase-1 
heterodimer, none of them proved successful. These included changing the buffer solutions 
and the dialysis hardware involved during the refolding process, along with extended 
purification techniques to further improve the quality of the samples to be refolded. The 
best insight I can offer is on the syntax of buffer addition, whether it is protein added to 
buffer or buffer added to protein. This syntax can change the refolding landscape by having 
drastic variations on protein concentration or buffer concentration in the initial moments 
of the refolding process. Further exploration of this process can be done by employing a 
burette to slowly add protein or buffer over the course of an experiment. Other examples 
may include higher volumes of buffer utilizing inexpensive inhibition via malonate, further 
exploration of dialysis hardware, or utilizing mammalian cells to produce active caspase-
1, sidestepping the refolding process entirely (Yamaguchi and Miyazaki 2014) 
 
Section 2. Caspase-3 Methods and Materials 
Caspase-3 Expression  
 Based on previously published methodologies (Denault et. Al. 2002; Romanowski 
et. Al 2005; Fang et. Al 2006), caspase-3 was expressed as a single peptide that utilized 
caspase-3’s autoproteolytic activity for activation during the purification steps. Caspase-3 
was expressed in a manner similar to that previously described for caspase-1. DNA for 
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NCBI reference NM_032991.2 was ordered from GenScript and was used as the target 
sequence for BLAST verification after the GATEWAY LR reactions.   
Procaspase-3 primers were designed based on this sequence with the GATEWAY 
flanking sequence and a C-terminal 6xHis tag, focusing on residues 150-401, respectively 
(pg 58). The DNA sequence was amplified and processed in a similar manner to the 
caspase-1 DNA utilizing DH5a E. coli cells. The PCR products were cleaned after each 
step using a QIAprep MINIprep column, followed by nanodrop (microvolume 
spectrophotometer) to access nucleic acid concentrations. This was then used for the 
GATEWAY protocol as described earlier. The corresponding procaspase-3 plasmid was 
used to transform BL21 DE3 pLysS using the growth and purification protocol described 
previously.  
The procaspase-3 zymogen plasmid was used to transform BL21 DE3 PLysS cells, 
which were subsequently grown on Amp+/ LB plates. After overnight incubation at 37oC, 
single colonies from each plate were picked and used to inoculate 30mL LB growths, which 
were grown at 37oC, 200 RPM overnight. 5ml of these growths were used to inoculate each 
liter of a 6x 1L Amp+/2xYT growth (prepared as described earlier), which were then grown 
at 37oC and 200 RPM for ~4 hours. Log phase growth was tracked using the OD600nm. Once 
OD600nm ≈ 0.8, the cultures are induced with 200 uM IPTG (final concentration). Once 
induced, the culture temperature was dropped to 25oC, and the cells were grown at 25oC, 
200 RPM, for 4 more hours. 
Cells were then harvested and centrifuged at 7,000 RPM, 4oC, for 35 minutes. The 
pellets were collected and 12g of pellet was homogenized with 100 mL of Lysis 
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Caspase-3 Primer with C-terminal fusion 6xHis-tag (Res 150-401) 
Forward Primer #1: 
ATTB-CASP3-150  
5’-GGC-TTC-GAA-GGA-GAT-AGA-ACC-ATG-GAG-AAC-ACT-GAA-AAC-3’ 
Underlined sections overlap with forward primers. 
Flanking region portion is in bold. 
 
Forward Primer #2: 
ATTB 
5’-GGGG-ACA-AGT-TTG-TAC-AAA-AAA-GCA-GGC-TTC-GAA-GGA-GAT-3’ 
Flanking region portion is in bold. 
 
Reverse Primer #1: 
CASPASE3-401 
5’-CTA-GTG-ATG-GTG-ATG-GTG-ATG-GTG-ATA-AAA-ATA-GAG-TTC-TTT-
TGT-3’  
Underlined section overlaps with reverse primers. 
 
Reverse Primer #2: 
ATTB-STOP-CASPASE3-401  
5’-GGGG-AC-CAC-TTT-GTA-CAA-GAA-AGC-TGG-GTC-CTA-GTG-ATG-GTG-
ATG-GTG-ATG-3’ 
Flanking region portion is in bold.                           5’-CAT-CAC-3’   
Underlined is stop codon and His-tag repeat           3’-GTA-GTG-5’ 
 
Table 6. Capase-3 Primers. Human caspase-3 zymogen primers (residues 150-401) used 
in the GATEWAY recombination process. Bold regions denote flanking attaB sequence. 
Underlined regions show primer overlap for construct extension. 
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Buffer (50 mM Tris pH 8.0 and 50 mM NaCl, filtered at 0.2 um) using a sonicator for 4 
minutes total, 0.5 seconds on, 0.5 seconds off. The homogenate was then centrifuged at 
35,000 RPM, 4oC, for 35 minutes and the supernatant was filtered on a 0.2um filter.  
 
Caspase-3 Purification and Validation 
The protein was purified using a gravity-flow Ni-NTA column, utilizing the 6xHis 
N-terminal tag on pro-caspase-3 provided by the pDEST14 vector. 35 mL of lysate was 
added to a 5mL Ni-NTA column previously washed with 200 mL MilliQ H2O. The lysate 
doped column was incubated for 1 hour with shaking at 4oC. The column was washed twice 
with 50 mL Wash Buffer (50 mM Tris-HCL pH 8.0, 500 mM NaCl, 20 mM imidazole pH 
8.0, filtered at 0.2 um) and once with 45 mL of Elution Buffer (50 mM Tris-HCL pH 8.0, 
150 mM NaCl, 250 mM imidazole pH 8.0, filtered at 0.2 um). At this point, the p17/p12 
bands are both present due to auto-proteolysis on the Ni-NTA column (pg 60).  
The caspase-3 containing samples previously validated via SDS-PAGE were 
pooled, and further purification was conducted (Fang et al. 2006). A sample was also 
collected to qualitatively validate capase-3 activity using the Caspase-3 Drug Discovery 
Kit (Enzo Life Sciences), a fluorometric assay that uses Ac-DEVD-AMC as a fluorogenic 
substrate (Denault et l. 2002, pg 61). Assays were conducted on 1000-fold dilution of Ni-
NTA columns in a black walled, clear bottom 96-well plate. The assay buffer contained 
150 mM PIPES pH 7, 50 mM NaCl, 20% sucrose, 0.2% CHAPS, 2 mM EDTA, and 20 
mM DTT that was added fresh prior to each assay. 
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Figure 13. Caspase-3 Ni-NTA SDS-PAGE. SDS-PAGE gel of caspase-3 after grav-
flow Ni-NTA purification and zymogen cleavage on Ni-NTA column. Lanes 2 through 5 
show crude pellet bands, lanes 7 and 8 show purified, cleaved caspase-3. Gel was stained 
using Coomassie Brilliant Blue. 
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Well 2x Buffer 
1000x 
Sample 
1x 
Sample 
MilliQ 
Ac-
DEVD-
AMC 
Ac-
DEVD-
CHO 
Small 
Molecule 
1000x Assay 50 µL 30 µL -- -- 20 µL -- -- 
1x Assay 50 µL -- 30 µL -- 20 µL -- -- 
Inhibitor 40 µL 30 µL -- -- 20 µL 10 µL -- 
Competition 49-40 µL 30 µL -- -- 20 µL -- 10-1 µL 
Background 50 µL -- -- 30 µL 20 µL -- -- 
Blank 50 µL -- -- 50 µL -- -- -- 
 
Figure 14. Caspase-3 Activity Data. (Top) Readout for activity assay to validate active 
protein based on Caspase-3 Drug Discovery Kit by Enzo Life Sciences and the protocol 
provided in “Expression, Purification, and Characterization of Caspases” by Jean-
Bernard Denault et Al. in Current Protocols in Protein Science (2002). Assay utilized 
fluorometric ligand Ac-DEVD-AMC. Excitation was measured at 380nm, emission was 
measured at 460nm with a cutoff at 435nm. (Bottom) Well compositions for 96-well 
assays. 
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Ni-NTA fractions were bag-dialyzed into 1L low salt Q-column buffer (25 mM 
Tris-HCL pH 8.0, 20 mM NaCl, 10 mM DTT, filtered at 0.2 um) for 2 hours and then 
another 1L for 24 hours. Pumps were primed on an AKTA HPLC for cation exchange 
chromatography using program Dual-Hi_Trap_Q_10mL_Equilibrate under Sprang > Sam 
(AKTA pure), the samples were loaded into the sample pump, and the program Dual-
Hi_Trap_Q_10mL_Fast_Run_No_Pump_Wash_Sam was run. Protein eluted at ~25 
mS/cm and was validated using SDS-PAGE (pg 63). The appropriate fractions were 
concentrated using a 10 MWCO concentrator, reducing the total volume down to 1 mL. 
This was then loaded into an FPLC with a G75 size exclusion column previously 
equilibrated with Size Exclusion Buffer (25 mM HEPEs pH 7.4, 50 mM NaCl, 1 mM 
EDTA, filtered at 0.2 um). The protein was eluted as a 120 kDa hetero-octamer using a 
flowrate of approximately 0.5 mL/min (pg 63) 
 
Caspase-3 Positive Control Crystal 
 Caspase-3 was successfully crystallized (pg 66) using previously published 
methodologies for hanging drop cocrystal experiments with Caspase-3 and the known 
inhibitor Ac-DEVD-CHO. This crystal was generated in 100 mM sodium citrate, 5% 
glycerol, 10 mM DTT, 12-18% PEG 6k (Rotonda et al. 1997) and was shot at the APS in 
Chicago, IL by Dr. T.C. Mou. Indexing was done using HKL2000; further data assessment 
was done using Phenix.Xtriage; molecular replacement was done using 
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Figure 15. Caspase-3 Q-column SDS-PAGE. SDS-PAGE gels of caspase-3 after Q-
column purification, with a Kaleidoscope Ladder (Lane 1) followed by Q-column 
fractions using an AKTA FPLC (lane 3-9) and the Ni-NTA fraction loaded into the Q-
column (lane 10). Gel was stained using Coomassie Brilliant Blue. 
 
Figure 16. Caspase-3 Size Exclusion SDS-PAGE. SDS-PAGE gels of caspase-3 after 
S-column purification on a G75 column, with a Kaleidoscope Ladder (Lane 1) followed 
by a Q-column fraction using an AKTA FPLC (lane 2), followed by fractions purified on 
a G75 S-column (Lane 3-10). Gel was stained using Coomassie Brilliant Blue. 
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Phenix.phaser and PDB:1PAU as a reference model (Rotonda et. Al. 1997); and refinement 
using was done using Phenix.refine along with visualization in Coot and Pymol. The final 
structure (pg 67) was contained in space group P212121, in a unit cell with parameters of a 
= 69.81Å, b = 84.62Å, c = 96.79Å, α = 90o, β = 90o, γ = 90o. The structure showed good 
completeness (93.8%) at the resolution shell for 1.74 Å, with 11270 to 12017 unique 
reflections in that resolution shell (2.08 – 1.74 Å), as calculated with Phenix.Xtriage. This 
is on par with other published caspase-ligand structures utilizing reversible inhibitors based 
on endogenous substrates (Rotonda et al. 1997, PDB: 1PAU; Fang et al 2006, PDB: 2H5I).  
 
Caspase-3 Cocrystals with Natural Products 
Based on the previous success of crystal generation with a positive control, further 
crystallographic trials were conducted with natural product inhibitors previously identified 
by the Stierle Lab. To this end, several 96-well sitting drop experiments were conducted 
with traditional 96-well crystal screens: JSGC I – IV (Lesley and Wilson 2005), PEG1-2 
(Qiagen), and 24-well hanging drop experiments with custom conditions (Plate 1: 0.1 M 
Sodium Citrate with 1.6 to 2.2 Ammonium Sulfate along the Y-axis, and pH 2.4 to 4.9 
along the X-axis; Plate 2: 0.1M Tris-HCl, 0.2M Ammonium Sulfate, 30-45% 2-methyl-
2,4-pentandiol along the Y-axis, pH 7 to 6 along the X-axis) at both 4oC and 25oC.  Ligands 
were prepared in DMSO at 6 mg/mL and mixed with caspase-3 at a ratio 20x the recorded 
IC50 (Mittl et al. 1997). Crystal plates were stored at 4 and 25
oC, screened using visible 
light microscopy to identify crystals and UV-microscopy to verify the crystals contain 
protein (Desbois et al 2013). 
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Conclusions and Future Directions 
 For the positive control experiment, we were able to successfully generate crystals 
of caspase-3 with Ac-DEVD-CHO at 1.75 Å (pg 66, 67) with a high level of completeness 
(93.8%). Concerning the cocrystal experiments with natural product inhibitors, 
microcrystals were generated for DNA 66 (pg 69, 70; Newman, Cragg, and Stierle et al. 
2017) and DNA 82 (unpublished) under the conditions in JCSG3 wells H9 and H10 (H9: 
0.1 M Citric acid pH 3.5, 1.6 M Ammonium Sulfate, final pH 4.0; H10: 2.0 M Sodium 
Chloride, 10% (w/v) PEG 6,000 respectively). Unfortunately, larger crystals could not be 
generated for diffraction studies, which were required for handling and transport. 
Microcrystals can be incredibly hard to isolate and unstable during transport to a beamline. 
While this project was more successful than the caspase-1 project, we were still 
unable to produce publishable results. The cocrystallization of caspase-3 with a small 
molecule inhibitor can be further explored by using the microcrystals generated as seeds 
for further crystallization studies. By moving the crystals to new solutions with high protein 
concentration, growing them to a diffractable size might be possible.  
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Figure 17. Caspase-3 and Ac-DEVD-CHO Crystals. Protein crystals of caspase-3 
bound to Ac-DEVD-CHO generated in 100 mM Na-citrate, 5% glycerol, 10 mM DTT, 
12-18% PEG 6k. Crystals diffracted at 1.74 A with 93% completeness. 
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Figure 18. Caspase-3 Crystal Screen Captures. (Left) Image capture of caspase-3 
positive control from the side. Green ribbon depicts the caspase-3 small subunit and the 
gray ribbon shows the large subunit. Green stick model represents Ac-DEVD-CHO, gray 
stick model represents cystine 285, the active residue which is responsible for proteolytic 
attack. (Right) Surface representation of caspase-3’s binding site viewed from the top 
down.  (Bottom) A closer zoom on the electrostatic potential map for the caspase-3 
binding site with Ac-DEVD-CHO bound. This further illustrates the S1 to S4 sites (lower 
right to upper left) represented in loops 1-4 (foreground). Images were collected using 
Pymol software. 
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Figure 19. Caspase-3 and DNA 82 Microcrystals. Human caspase-3 sitting drop 
cocrystal experiments with natural product inhibitor DNA 82. (Top) Image depicts 
microcrystals from JCSG 3 well H9. (Middle) Image depicts microcrystals from JCSG 3 
well H10. Images were taken using light microscope in the Crystallography Core at 
University of Montana. (Bottom) Natural product inhibitor DNA 82. 
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Figure 20. Caspase-3 and DNA 66 Microcrystals. Human caspase-3 sitting drop 
cocrystal experiments with natural product inhibitor DNA 66. (Top) Image depicts 
microcrystals from JCSG 3 well H9. (Middle) Image depicts microcrystals from JCSG 3 
well H10. Images were taken using light microscope in the Crystallography Core at 
University of Montana. (Bottom) Natural product inhibitor DNA 66. 
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This does not solve the issue of peptide stabilization, which I believe is a 2-fold 
problem (ligand length and protein dynamics) but exemplified by one process (dynamics). 
The action of the caspases is highly dynamic (Fang et al. 2006); there is a substantial 
amount of domain translocation during substrate binding, lysis, and release, particularly 
around the ligand-binding cleft and the S4-S3 sites. This means that stabilizing the peptide 
complex, which is essential to high resolution protein crystals, can be extremely difficult 
and requires a host of interactions at spatially distinct sites (S1 to S4, not just S1). While 
this can be accomplished with simple, extended peptide chains, it is not a trivial task for 
non-peptide-based inhibitors. To this end, I think crystallization would have a higher 
probability for success utilizing inhibitors with either a higher affinity or with more 
extended structure. These might be capable of stabilizing more spatially distinct sites in the 
caspase-3 binding cleft, similar to that of peptide-based caspase inhibitors. A similar 
approach was employed when developing the NS3 protease inhibitor, Boceprevir (Howe 
et al 2013). 
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